Latest Insider Transactions at Nektar Therapeutics (NKTR)
This section provides a real-time view of insider transactions for Nektar Therapeutics (NKTR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEKTAR THERAPEUTICS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEKTAR THERAPEUTICS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2024
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
19,500
-7.1%
|
$19,500
$1.2 P/Share
|
|
May 17
2024
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,260
-2.65%
|
$6,260
$1.75 P/Share
|
|
May 17
2024
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
7,355
-2.78%
|
$7,355
$1.75 P/Share
|
|
May 17
2024
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
16,650
-1.89%
|
$16,650
$1.75 P/Share
|
|
May 10
2024
|
Deep Track Capital, LP |
SELL
Open market or private sale
|
Indirect |
56,000
-0.3%
|
$56,000
$1.78 P/Share
|
|
Feb 20
2024
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
20,033
-2.23%
|
$0
$0.68 P/Share
|
|
Feb 20
2024
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,606
-3.11%
|
$0
$0.68 P/Share
|
|
Feb 20
2024
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
9,014
-3.29%
|
$0
$0.68 P/Share
|
|
Nov 17
2023
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,179
-2.86%
|
$0
$0.49 P/Share
|
|
Nov 17
2023
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
9,646
-3.4%
|
$0
$0.49 P/Share
|
|
Nov 17
2023
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
19,877
-2.16%
|
$0
$0.49 P/Share
|
|
Sep 18
2023
|
Myriam Curet Director |
SELL
Open market or private sale
|
Direct |
4,359
-13.72%
|
$0
$0.69 P/Share
|
|
Sep 18
2023
|
Jeffrey Robert Ajer Director |
SELL
Open market or private sale
|
Direct |
4,359
-11.32%
|
$0
$0.69 P/Share
|
|
Aug 16
2023
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
19,998
-2.13%
|
$0
$0.78 P/Share
|
|
Aug 16
2023
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,221
-2.8%
|
$0
$0.78 P/Share
|
|
Aug 16
2023
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
9,703
-3.31%
|
$0
$0.78 P/Share
|
|
Jun 14
2023
|
Roy A Whitfield Director |
SELL
Open market or private sale
|
Direct |
30,000
-12.18%
|
$0
$0.57 P/Share
|
|
May 16
2023
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
9,791
-3.23%
|
$0
$0.72 P/Share
|
|
May 16
2023
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
20,361
-2.12%
|
$0
$0.72 P/Share
|
|
May 16
2023
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,543
-2.84%
|
$0
$0.72 P/Share
|
|
Feb 16
2023
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
10,484
-3.34%
|
$31,452
$3.0 P/Share
|
|
Feb 16
2023
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
19,635
-2.0%
|
$58,905
$3.0 P/Share
|
|
Feb 16
2023
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,267
-3.17%
|
$30,801
$3.0 P/Share
|
|
Feb 16
2023
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,275
-3.03%
|
$24,825
$3.0 P/Share
|
|
Nov 16
2022
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
38,014
-3.73%
|
$114,042
$3.57 P/Share
|
|
Nov 16
2022
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,095
-3.31%
|
$33,285
$3.57 P/Share
|
|
Nov 16
2022
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,690
-3.09%
|
$26,070
$3.57 P/Share
|
|
Nov 16
2022
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
13,460
-4.11%
|
$40,380
$3.57 P/Share
|
|
Sep 23
2022
|
Myriam Curet Director |
SELL
Open market or private sale
|
Direct |
4,198
-11.67%
|
$12,594
$3.16 P/Share
|
|
Sep 23
2022
|
Jeffrey Robert Ajer Director |
SELL
Open market or private sale
|
Direct |
4,198
-9.83%
|
$12,594
$3.16 P/Share
|
|
Sep 22
2022
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
15,300
-2.88%
|
$15,300
$1.93 P/Share
|
|
Sep 16
2022
|
Roy A Whitfield Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+3.98%
|
-
|
|
Sep 16
2022
|
R Scott Greer Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+3.25%
|
-
|
|
Sep 16
2022
|
Karin Eastham Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+30.51%
|
-
|
|
Sep 16
2022
|
Myriam Curet Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+22.09%
|
-
|
|
Sep 16
2022
|
Robert Chess |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+4.19%
|
-
|
|
Sep 16
2022
|
Diana Brainard Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+26.32%
|
-
|
|
Sep 16
2022
|
Jeffrey Robert Ajer Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,200
+19.28%
|
-
|
|
Sep 13
2022
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
21,267
-62.0%
|
$63,801
$3.61 P/Share
|
|
Aug 18
2022
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
73,716
-18.39%
|
$294,864
$4.65 P/Share
|
|
Aug 16
2022
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
10,560
-2.57%
|
$42,240
$4.76 P/Share
|
|
Aug 16
2022
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,189
-1.12%
|
$12,756
$4.76 P/Share
|
|
Aug 16
2022
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,006
-0.6%
|
$8,024
$4.76 P/Share
|
|
Aug 16
2022
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
13,759
-1.33%
|
$55,036
$4.76 P/Share
|
|
Aug 15
2022
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+24.71%
|
-
|
|
Aug 15
2022
|
Mark Andrew Wilson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
165,938
+36.85%
|
-
|
|
Aug 15
2022
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
165,938
+33.0%
|
-
|
|
Aug 15
2022
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
410,625
+28.47%
|
-
|
|
May 16
2022
|
John Northcott SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,592
-2.02%
|
$13,776
$3.95 P/Share
|
|
May 16
2022
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,136
-2.59%
|
$9,408
$3.95 P/Share
|